MEPs water down price transparency proposal as clash with ministers looms
This article was originally published in Scrip
An influential European Parliament committee has rejected proposals by the European Commission to reduce maximum pricing and reimbursement times for new medicines, and has also watered down plans to enforce those times more strictly. The committee did, however, come out in favour of shorter decision-making periods for generic drugs, and called for greater transparency on conflicts of interest within decision-making bodies.
You may also be interested in...
The Conservative Party's victory in the UK general election means the Brexit withdrawal deal will be able to pass. The UK will leave the EU by 31 January and enter a transition period during which medicines regulation will remain broadly unchanged.
Health ministers have called for more action on access to medicines, including a new EU work agenda, rebuilding Europe’s manufacturing capabilities, further action on pricing, and greater leeway for member states to mitigate drug shortages by restricting parallel exports.